Recommended Citation
Hernandez-Franco, Juan F.; Jan, Imran M.; Elzey, Bennett D.; and HogenEsch, Harm, "Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity" (2024). Purdue University Libraries Open Access Publishing Fund. Paper 181.
http://dx.doi.org/10.1038/s41541-024-00943-8
DOI
10.1038/s41541-024-00943-8
Date of this Version
8-17-2024
Abstract
A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8+ T cell depletion but not by CD4+ T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.
Comments
This is the publisher PDF of Hernandez-Franco, J.F., Jan, I.M., Elzey, B.D. et al. Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity. npj Vaccines 9, 149 (2024). This article is distributed under a CC-BY license, and is available at DOI: 10.1038/s41541-024-00943-8.